New! Sign up for our free email newsletter.
Science News
from research organizations

Harnessing the power of predatory bacteria as a 'living antibiotic'

November 23, 2016
Wellcome Trust
A naturally occurring predatory bacterium is able to work with the immune system to clear multi-drug resistant Shigella infections in zebrafish, according to a study.

A naturally occurring predatory bacterium is able to work with the immune system to clear multi-drug resistant Shigella infections in zebrafish, according to a study published today in Current Biology.

It is the first time the predatory bacterium Bdellovibrio bacteriovorus has been successfully used as an injected anti-bacterial therapy and represents an important step in the fight against drug-resistant infections, or 'superbugs'.

Shigella infection is responsible for over 160 million illnesses and over 1 million deaths every year -- and is a common cause of 'travellers' diarrhea.' Cases of drug-resistant Shigella are also on the rise as, although the diarrhea usually clears up without treatment, antibiotics are often used even in mild cases to stop the diarrhea faster. Resistance to antibiotics has prompted a team of researchers from Imperial College London and Nottingham University to look to the natural environment for creative solutions to this problem.

To investigate Bdellovibrio's ability to control drug resistant Gram-negative infections, researchers injected zebrafish larvae with a lethal dose of Shigella flexneri strain M90T, resistant to both streptomycin and carbenicillin antibiotics. Bdellovibrio was then injected into the larvae's infection site, and a decrease in the number of Shigella was seen. In the absence of Bdellovibrio, zebrafish were unable to control the replication of Shigella and levels of the bacteria rose.

Wellcome Research Career Development Fellow Dr Serge Mostowy, co-lead author from Imperial College London said: "This study really shows what a unique and interesting bacterium Bdellovibrio is as it presents this amazing natural synergy with the immune system and persists just long enough to kill prey bacteria before being naturally cleared. It's an important milestone in research into the use of a living antibiotic that could be used in animals and humans."

Bdellovibrio can invade and kill a range of Gram-negative bacteria, such as E. coli and Salmonella, in the natural environment. Previous research has shown that it can reduce pathogen numbers in the stomach of chickens when taken as an oral therapy, but there is growing need to develop therapies to target infections in wounds and organs. Successful use of Bdellovibrio highlights its potential uses in tackling a range of drug-resistant Gram-negative bacterial infections that can develop in hospital patients.

Professor Liz Sockett, co-lead author from The University of Nottingham said: "This has been a truly ground-breaking collaboration that shows therapeutic Bdellovibrio in action inside the translucent living zebrafish. The predatory action of the Bdellovibrio breaks the Shigella-pathogen cells and this stimulates the white blood cells; redoubling their 'efforts' against the pathogen and leading to increased survival of the zebrafish 'patients'."

Remarkably, Bdellovibrio is also able to reduce pathogen load in immunocompromised zebrafish larvae that have been depleted of white blood cells. However, survival is significantly greater in immune-competent zebrafish, showing that Bdellovibrio's maximum therapeutic benefit comes from its ability to work cooperatively with the host's own immune system.

Dr Michael Chew, Science Portfolio Advisor at Wellcome said: "It may be unusual to use a bacterium to get rid of another, but in the light of the looming threat from drug resistant infections the potential of beneficial bacteria-animal interactions should not be overlooked. We are increasingly relying on last line antibiotics, and this innovative study demonstrates how predatory bacteria could be an important additional tool to drugs in the fight against resistance."

Story Source:

Materials provided by Wellcome Trust. Note: Content may be edited for style and length.

Journal Reference:

  1. N. Sadananda Singh, Nan Shao, Janel R. McLean, Mayalagu Sevugan, Liping Ren, Ting Gang Chew, Andrea Bimbo, Reetu Sharma, Xie Tang, Kathleen L. Gould, Mohan K. Balasubramanian. SIN-Inhibitory Phosphatase Complex Promotes Cdc11p Dephosphorylation and Propagates SIN Asymmetry in Fission Yeast. Current Biology, 2011; 21 (23): 1968 DOI: 10.1016/j.cub.2011.10.051

Cite This Page:

Wellcome Trust. "Harnessing the power of predatory bacteria as a 'living antibiotic'." ScienceDaily. ScienceDaily, 23 November 2016. <>.
Wellcome Trust. (2016, November 23). Harnessing the power of predatory bacteria as a 'living antibiotic'. ScienceDaily. Retrieved December 10, 2023 from
Wellcome Trust. "Harnessing the power of predatory bacteria as a 'living antibiotic'." ScienceDaily. (accessed December 10, 2023).

Explore More
from ScienceDaily